In our study, we included participants from two double-blind, randomized, placebo-controlled trials [19, 20] to evaluate the effect of cilostazol treatment on plasma PCSK9 levels and the potential mechanisms of action in patients with PAD or at high risk of CVD. Here, PCSK9 is linked to peripheral arterial disease.